Karyon Ltd's operations focus on the discovery, IP protection and early development of carrier peptides that target specific tissues. The targeting peptides are identified from ex vivo patient tumour tissue and further synthetically modified at Karyon Ltd. Linking a diagnostic marker or therapeutic regimen to the targeting peptide enriches compound concentration in the target organ.
|Karyon targeting unit||Target indications|
Tumour cell targeting peptides
|Sarcoma, melanoma, kaposi's sarcoma|
|Karyon AETP |
Activated endothelium targeting peptides
|Conditions of angiogenic origin|
Non small cell lung cancer targeting peptide
|Non small cell lung cancer|
|Karyon LMC |
|Colon cancer lung metastases|
Oral cancer targeting peptides
|Lingual and gingival cancer forms|
Lymph sentinel node metastases
|Head and neck lymph sentinel node metastases|
Karyon Ltd's scientists are pleased to assist your company's diagnostic or therapeutic compound find its tumour target.